2499664-52-5

STM3006 is a highly potent, selective, and orally active inhibitor of METTL3 (IC50: 5 nM). STM3006 can reduce the m6A level, promote the formation of dsRNA, trigger a cell-intrinsic interferon response, and enhance the killing effect of T cells on tumors. STM3006 has anti-tumor activity, and its combination with anti-PD-1 immunotherapy yields better results[1][2].

[1] Andrew A Guirguis, et al. Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity.Cancer Discov. 2023 Oct 5;13(10):2228-2247. DOI:10.1158/2159-8290.CD-23-0007
[2] Brichkina A, et al. Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy. Signal Transduct Target Ther. 2023 Dec 11;8(1):448. DOI:10.1038/s41392-023-01696-x